{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:08:46Z","timestamp":1782140926453,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010564","name":"German Center for Lung Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hector Foundation II"},{"name":"Margarete-Clemens Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.lungcan.2020.08.007","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T21:02:08Z","timestamp":1598043728000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"P.","family":"Christopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-2400","authenticated-orcid":false,"given":"M.","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Roeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Saalfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-8506","authenticated-orcid":false,"given":"M.","family":"Janning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-8884","authenticated-orcid":false,"given":"F.","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Magios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kazdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Volckmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bochtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Endris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Penzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.F.","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Heussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"El Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Muley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Faehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Heukamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wermke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Loges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-055X","authenticated-orcid":false,"given":"M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2020.08.007_bib0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdy474","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Planchard","year":"2019","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.007_bib0010","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","article-title":"Five-year survival in EGFR-Mutant metastatic lung adenocarcinoma treated with EGFR-TKIs","volume":"11","author":"Lin","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2020.08.007_bib0015","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 mutations on outcome in EGFR-Mutated patients treated with first-line tyrosine kinase inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.08.007_bib0020","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2147\/OTT.S125397","article-title":"EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?","volume":"10","author":"Joshi","year":"2017","journal-title":"Onco. Targets Ther."},{"issue":"13","key":"10.1016\/j.lungcan.2020.08.007_bib0025","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.007_bib0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ijc.32133","article-title":"Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3,000 Heidelberg cases","volume":"145","author":"Volckmar","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.08.007_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2020.08.007_bib0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00428-010-1000-y","article-title":"EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation testing in NSCLC","volume":"458","author":"Penzel","year":"2011","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.007_bib0045","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00018013","article-title":"EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype","volume":"43","author":"Warth","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"4 Supplement","key":"10.1016\/j.lungcan.2020.08.007_bib0050","article-title":"Abstract P3-17-03: Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial","volume":"78","author":"Bartlett","year":"2018","journal-title":"Cancer Res."},{"issue":"Supplement_5","key":"10.1016\/j.lungcan.2020.08.007_bib0055","article-title":"1581P Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)","volume":"30","author":"Ma","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.08.007_bib0060","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","article-title":"L.R.h.n. For the onco, A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson\u2019s index","volume":"93","author":"Colinet","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"27","key":"10.1016\/j.lungcan.2020.08.007_bib0065","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1002\/sim.5874","article-title":"Estimating the correlation of bivariate failure times under censoring","volume":"32","author":"Schemper","year":"2013","journal-title":"Stat. Med."},{"key":"10.1016\/j.lungcan.2020.08.007_bib0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2018.01.005","article-title":"Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: long-term follow-up of a large patient cohort","volume":"117","author":"Okamoto","year":"2018","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.007_bib0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cllc.2018.10.009","article-title":"Impact of Exon 19 deletion subtypes in EGFR-mutant metastatic non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors","volume":"20","author":"Rossi","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2020.08.007_bib0080","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.007_bib0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jcb.23400","article-title":"Links between mutant p53 and genomic instability","volume":"113","author":"Hanel","year":"2012","journal-title":"J. Cell. Biochem."},{"issue":"33","key":"10.1016\/j.lungcan.2020.08.007_bib0090","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.18632\/oncotarget.26886","article-title":"Defining molecular risk in ALK(+) NSCLC","volume":"10","author":"Christopoulos","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.08.007_bib0095","article-title":"Tumor mutation burden and efficacy of EGFR-Tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","author":"Offin","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"Supplement_5","key":"10.1016\/j.lungcan.2020.08.007_bib0100","article-title":"1479OIntegrated genomic and DNA methylation analyses of non-small cell lung cancer patients with brain metastases","volume":"30","author":"Fan","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7287","key":"10.1016\/j.lungcan.2020.08.007_bib0105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature08803","article-title":"Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal","volume":"464","author":"Sotillo","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.007_bib0110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.007_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00107","article-title":"Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non\u2013small-cell lung cancer","author":"Aggarwal","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lungcan.2020.08.007_bib0120","doi-asserted-by":"crossref","first-page":"v149","DOI":"10.1093\/annonc\/mdz243.015","article-title":"Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer","volume":"30","author":"Chen","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.08.007_bib0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.007_bib0130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.1993.140","article-title":"Performance status assessment in cancer patients. An inter-observer variability study","volume":"67","author":"Sorensen","year":"1993","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2020.08.007_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13000-019-0840-2","article-title":"The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies","volume":"14","author":"Ho","year":"2019","journal-title":"Diagn. Pathol."},{"issue":"12","key":"10.1016\/j.lungcan.2020.08.007_bib0140","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2020.08.007_bib0145","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ebiom.2019.03.023","article-title":"Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer","volume":"42","author":"Chen","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lungcan.2020.08.007_bib0150","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/OTT.S231257","article-title":"MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF\/c-Met Axis","volume":"13","author":"Liang","year":"2020","journal-title":"Onco. Targets Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2020.08.007_bib0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/PO.19.00333","article-title":"Targeting HER2 alterations in non\u2013small-cell lung cancer: a comprehensive review","author":"Zhao","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.08.007_bib0160","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jval.2018.04.1372","article-title":"Budget impact of next-generation sequencing for molecular assessment of advanced non-small cell lung cancer","volume":"21","author":"Yu","year":"2018","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.lungcan.2020.08.007_bib0165","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2020.08.007_bib0170","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.08.007_bib0175","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung Cancer","author":"Noronha","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.007_bib0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non\u2013small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.08.007_bib0185","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1016\/j.jtho.2019.08.441","article-title":"OA07.01 Osimertinib plus platinum\/pemetrexed in newly-diagnosed advanced EGFRm-positive NSCLC; the phase 3 FLAURA2 study","volume":"14","author":"J\u00e4nne","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.08.007_bib0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jtho.2016.10.012","article-title":"Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung Cancer","volume":"12","author":"Kim","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"Supplement_5","key":"10.1016\/j.lungcan.2020.08.007_bib0195","article-title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","volume":"30","author":"Gray","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.08.007_bib0200","doi-asserted-by":"crossref","first-page":"33505","DOI":"10.1038\/srep33505","article-title":"Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients","volume":"6","author":"Riediger","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.lungcan.2020.08.007_bib0205","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.lungcan.2012.05.110","article-title":"Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT\u2011)PET","volume":"77","author":"Scheffler","year":"2012","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2020.08.007_bib0210","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/JTO.0000000000000570","article-title":"Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients","volume":"10","author":"K\u00f6nig","year":"2015","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:45:12Z","timestamp":1759236312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220305791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"alternative-id":["S0169500220305791"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}